Abstract
The chloroform and hexane fractions and their sub-fractions of Polygonum bistorta (Polygonaceae) were evaluated for their cytotoxic activity against P338 (Murine lymphocytic leukaemia), HepG2 (Hepatocellular carcinoma), J82 (Bladder transitional carcinoma), HL60 (Human leukaemia), MCF7 (Human breast cancer) and LL2 (Lewis lung carcinoma) cancer cell lines in culture. Both the chloroform and hexane fractions and a few of their sub-fractions showed moderate to very good activity against P388, HL60 and LL2 cancer cell lines. Both active and non-active fractions were further investigated for their chemical constituents. A total of nine compounds, viz. 24(E)-ethylidenecycloartanone (1), 24(E)-ethylidenecycloartan-3 α-ol (2), cycloartane-3,24-dione (3), 24-methylenecycloartanone (4), friedelin (5), 3 -β friedelinol (6), β -sitosterol (7), γ-sitosterol (8) and β-sitosterone (9) were isolated. One of the pure compounds, 24(E)- ethylidenecycloartanone 1, which was obtained in sufficient quantity, was tested for its cytotoxicity against P388, LL2, HL60 and WEHI164 (Murine fibrosarcoma) cancer cell lines but was found to have no activity even at a concentration of 100 μg/mL.
Keywords: Polygonum bistorta, cycloartane triterpenoids, β-sitosterol, cytotoxic activity, MTT assay, cancer cell lines
Medicinal Chemistry
Title: Evaluation of Polygonum bistorta for Anticancer Potential Using Selected Cancer Cell Lines
Volume: 3 Issue: 2
Author(s): Karuppiah Pillai Manoharan, Daiwen Yang, Annie Hsu and Benny Tan Kwong Huat
Affiliation:
Keywords: Polygonum bistorta, cycloartane triterpenoids, β-sitosterol, cytotoxic activity, MTT assay, cancer cell lines
Abstract: The chloroform and hexane fractions and their sub-fractions of Polygonum bistorta (Polygonaceae) were evaluated for their cytotoxic activity against P338 (Murine lymphocytic leukaemia), HepG2 (Hepatocellular carcinoma), J82 (Bladder transitional carcinoma), HL60 (Human leukaemia), MCF7 (Human breast cancer) and LL2 (Lewis lung carcinoma) cancer cell lines in culture. Both the chloroform and hexane fractions and a few of their sub-fractions showed moderate to very good activity against P388, HL60 and LL2 cancer cell lines. Both active and non-active fractions were further investigated for their chemical constituents. A total of nine compounds, viz. 24(E)-ethylidenecycloartanone (1), 24(E)-ethylidenecycloartan-3 α-ol (2), cycloartane-3,24-dione (3), 24-methylenecycloartanone (4), friedelin (5), 3 -β friedelinol (6), β -sitosterol (7), γ-sitosterol (8) and β-sitosterone (9) were isolated. One of the pure compounds, 24(E)- ethylidenecycloartanone 1, which was obtained in sufficient quantity, was tested for its cytotoxicity against P388, LL2, HL60 and WEHI164 (Murine fibrosarcoma) cancer cell lines but was found to have no activity even at a concentration of 100 μg/mL.
Export Options
About this article
Cite this article as:
Pillai Manoharan Karuppiah, Yang Daiwen, Hsu Annie and Tan Kwong Huat Benny, Evaluation of Polygonum bistorta for Anticancer Potential Using Selected Cancer Cell Lines, Medicinal Chemistry 2007; 3 (2) . https://dx.doi.org/10.2174/157340607780059495
DOI https://dx.doi.org/10.2174/157340607780059495 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Receptor Tyrosine Kinase Kit and Gastrointestinal Stromal Tumours: An Overview
Current Medicinal Chemistry Human T-Cell Leukemia Virus Type 1: Transition from Latent Infection to Pathogenic Progression and Implications for Molecular Therapy
Current Cancer Therapy Reviews Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Tetraspanins - Gateways for Infection
Infectious Disorders - Drug Targets A Role for SHIP in Stem Cell Biology and Transplantation
Current Stem Cell Research & Therapy Antibodies as Crypts of Antiinfective and Antitumor Peptides
Current Medicinal Chemistry Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials
Current Cancer Drug Targets The Effect of Casein Kinase 2 Inhibition on three Leukemic Cell Lines
Current Drug Therapy Histamine and Histamine Receptor Antagonists in Cancer Biology
Inflammation & Allergy - Drug Targets (Discontinued) The Use of Temozolomide for the Treatment of Malignant Tumors: Clinical Evidence and Molecular Mechanisms of Action
Recent Patents on Anti-Cancer Drug Discovery Immunotherapy Resistance Mechanisms in Renal Cell Cancer
Current Signal Transduction Therapy Flavonoids in Human Health: From Structure to Biological Activity
Current Nutrition & Food Science Structural and Functional Organization of miRNAs
Current Pharmacogenomics Interferon Treatment in Patients with Hypereosinophilia
Current Drug Targets New and Highly Potent Antitumor Natural Products from Marine-Derived Fungi: Covering the Period from 2003 to 2012
Current Topics in Medicinal Chemistry Phenothiazine Derivatives as Potential Antiproliferative Agents: A Mini- Review
Mini-Reviews in Organic Chemistry Multiple-Target Drugs: Inhibitors of Heat Shock Protein 90 and of Histone Deacetylase
Current Drug Targets Cancer “Stemness”- Regulating MicroRNAs: Role, Mechanisms and Therapeutic Potential
Current Drug Targets Biological Activities of Yarrow Species (Achillea spp.)
Current Pharmaceutical Design